Shares of Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) reached a new 52-week high during trading on Tuesday following insider buying activity. The stock traded as high as C$11.42 and last traded at C$11.33, with a volume of 3640 shares trading hands. The stock had previously closed at C$9.50.
Specifically, Director Jeffrey Hackman purchased 15,000 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, May 19th. The stock was purchased at an average cost of C$9.77 per share, for a total transaction of C$146,580.00.
Fennec Pharmaceuticals Stock Up 19.4%
The stock has a 50-day moving average of C$8.30 and a 200-day moving average of C$8.46. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. The company has a market cap of C$218.69 million, a PE ratio of -192.10 and a beta of 0.25.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- Find and Profitably Trade Stocks at 52-Week Lows
- Top 5 Stocks Hedge Funds Are Buying Right Now
- What Does Downgrade Mean in Investing?
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- What Are Dividend Contenders? Investing in Dividend Contenders
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
